Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pacira Pharm Inc 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 USA

www.pacira.com Employees: 790 P: 650-242-8052

Sector:

Medical

Description:

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.

Key Statistics

Overview:

Market Capitalization, $K 1,113,383
Enterprise Value, $K 1,142,603
Shares Outstanding, K 43,021
Annual Sales, $ 700,970 K
Annual Net Income, $ -99,560 K
Last Quarter Sales, $ 179,520 K
Last Quarter Net Income, $ 5,430 K
EBIT, $ 98,840 K
EBITDA, $ 180,850 K
60-Month Beta 0.23
% of Insider Shareholders 6.40%
% of Institutional Shareholders 99.73%
Float, K 40,268
% Float 93.60%
Short Interest 7,344
Short Float 17.07%
Short Volume Ratio 0.46

Growth:

1-Year Return 33.44%
3-Year Return -34.03%
5-Year Return -65.13%
5-Year Revenue Growth 66.49%
5-Year Earnings Growth 172.09%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.70 on 11/06/25
Next Earnings Date 02/26/26
Earnings Per Share ttm 2.03
EPS Growth vs. Prev Qtr -2.13%
EPS Growth vs. Prev Year -13.21%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PCRX Ratios

Ratio
Price/Earnings ttm 12.84
Price/Earnings forward 13.03
Price/Earnings to Growth N/A
Return-on-Equity % 12.83%
Return-on-Assets % 6.57%
Profit Margin % -14.20%
Debt/Equity 0.52
Price/Sales 1.60
Price/Cash Flow 6.04
Price/Book 1.61
Book Value/Share 16.19
Interest Coverage -2.81
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar